The company also offers platform-agnostic next-generation sequencing tests and a suite of sample prep and thermal cycling instruments.

The Boston-based digital pathology firm's updated US Food and Drug Administration clearance will help it to quickly validate its software with new hardware combinations.

The firm saw growth in its core laboratory segment but declines in molecular, point of care, and rapid diagnostics.

The agency said that the test is unnecessary for the screening of whole blood and blood components that are screened with nucleic acid tests and core antigen tests.

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

The US Food and Drug Administration granted clearances for infectious disease tests, digital pathology software, and hematology analyzers, among other in vitro diagnostic technologies.

The US Food and Drug Administration granted clearances for infectious disease tests, digital pathology software, and hematology analyzers, among other in vitro diagnostic technologies.

The company's next-generation sequencing-based test is used to aid the detection of cancers in patients with indeterminate ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

The Determine Antenatal Care Panel is used for the simultaneous detection of infectious diseases that threaten maternal and pediatric health.

Last week, readers were most interested in a story about an extended collaboration between Personalis and Tempus to include colorectal cancer.

The partnership will initially focus on low-abundance biomarkers supporting translational research in Alzheimer's disease.